Application No.: 10/049,419

Art Unit 1623

Preliminary Amendment with Request for Continued Examination

AMENDMENTS TO THE CLAIMS

Docket No.: 1422-0514P

This listing of claims will replace all prior versions, and listings, of claims in the

application.

Listing of Claims:

1-32. (Canceled)

33. (Currently Amended) A method of treating an autoimmune disease, anemia,

diabetes, septic shock, inflammatory enteropathy, chronic articular rheumatism, multiple

sclerosis, uveitis or an allergic disease, wherein the method comprises:

administering a fucoidan derived from Kjellmaniella crassifolia and/or a degradation

product thereof to a subject in need thereof for treating said autoimmune disease, anemia,

diabetes, septic shock, inflammatory enteropathy, chronic articular rheumatism, multiple

sclerosis, uveitis or said allergic disease. disease,

wherein the fucoidan is at least one substance selected from the group consisting of

glucuronic acid-containing fucoidan, glucuronic acid non-containing fucoidan and sulfated

fucogalactan.

34-36. (**Cancelled**)

37. (Previously Presented) The method according to claim 33, wherein the disease is an

allergic disease requiring suppression of IgE production.

Application No.: 10/049,419 Docket No.: 1422-0514P

Art Unit 1623

Preliminary Amendment with Request for Continued Examination

38. (Previously Presented) The method according to claim 33, wherein the fucoidan

and/or a degradation product thereof are orally administered.

39-60. (Cancelled)

61. (Previously Presented) The method according to claim 33, wherein a food, drink or

feed containing the fucoidan and/or a degradation product thereof as an effective ingredient is

used.

62. (Previously Presented) The method according to claim 33, wherein a cosmetic

containing the fucoidan and/or a degradation product thereof as an effective ingredient is used.

63. (Previously Presented) The method according to claim 62, wherein the cosmetic is

percutaneously administered.